Ocular Therapeutix Inc (OCUL) Reports -50.13% Fall From For 52 Week High, It’s Always Darkest Before The Dawn

Ocular Therapeutix Inc (NASDAQ:OCUL) does about 2.75M shares in volume on a normal day but saw 2314768 shares change hands in Monday’s trading. The company now has a market cap of 873.58M USD. Its current market price is $5.64, marking a decrease of -0.35% compared to the previous close of $5.66. The 52 week high reached by this stock is $11.31 whilst the lowest price level in 52 weeks is $2.00.

Ocular Therapeutix Inc (OCUL) has a 20-day trading average at $5.57 and the current price is -50.13% off the 52-week high compared with 182.71% distance from its 52-week low. The 50-day simple moving average of the closing price is $7.76 and its 200-day simple moving average is $4.97. If we look at the stock’s price movements over the week, volatility stands at 8.51%, which increases to 10.95% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 41.51 to suggest the stock is neutral.

The consensus objective for the share price is $14.50, suggesting that the stock has a potential upside of 61.1% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on February 09, 2024 when BofA Securities initiated the stock to “Buy” and issued a price target of $15. Berenberg resumed its price target at $15.

Ocular Therapeutix Inc (OCUL) stock is down -2.76% over the week and -29.41% over the past month. Its price is 26.46% year-to-date and -9.76% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of -0.26 above consensus estimates by 0.04. The company’s next earnings report forecasts estimating quarterly EPS at -0.2 and -1.02 for whole year. Expected sales for next quarter are $16.73M, which analysts say will come at $66.94M for the current fiscal year and next year at $78.88M. In addition, estimates put the company’s current quarterly revenue at an average of $16.03M.

To reach the target analysts have set, the stock logically needs to grow 61.1 percent from here.

The company has a return on investment of -23.97% and return on equity of -55.19%. The beta has a value of 1.41. Price to book ratio is 2.14 and price to sales ratio is 14.60.